NEUROLOGY 2005;64:1444-1445
© 2005 American Academy of Neurology
Brief Communications
EGFR tyrosine kinase domain mutations in human gliomas
Y. Marie, MSc,
A. F. Carpentier, MD, PhD,
A.M.P. Omuro, MD,
M. Sanson, MD, PhD,
J. Thillet, PhD,
K. Hoang-Xuan, MD, PhD and
J. -Y. Delattre, MD
From Department of Neurology Mazarin and Institut National de la Santé et de la Recherche Médicale (INSERM) UMR-495 (Y. Marie, and Drs. Carpentier, Sanson, Thillet, Hoang-Xuan, and Delattre), Hôpital de la Pitié-Salpêtrière, Paris, France; and Department of Neurology (Dr. Omuro), Memorial Sloan-Kettering Cancer Center, New York, NY.
Address correspondence and reprint requests to Dr. A Carpentier, Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, 47 bd de l’Hopital, Paris, France; e-mail: antoine.carpentier{at}psl.ap-hop-paris.fr
Gefitinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor effective in patients with lung cancer with mutations in exons 19 and 21 of the EGFR tyrosine kinase domain. In this study, the authors tested the presence of such mutations in 95 gliomas including glioblastomas, anaplastic oligodendrogliomas, and low-grade gliomas. No mutation was found, which suggests that the biology of EGFR in gliomas is different from lung cancer and that this may be a factor in the resistance of glioblastomas to gefitinib.
Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 26 issue to find the title link for this article.
Received October 28, 2004. Accepted in final form December 10, 2004.
This article has been cited by other articles:
|
|
|
|
 
J. J. Raizer, L. E. Abrey, A. B. Lassman, S. M. Chang, K. R. Lamborn, J. G. Kuhn, W.K. A. Yung, M. R. Gilbert, K. A. Aldape, P. Y. Wen, et al.
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Neuro Oncology,
January 1, 2010;
12(1):
95 - 103.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Ann. Onc.,
September 1, 2009;
20(9):
1596 - 1603.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Karpel-Massler, U. Schmidt, A. Unterberg, and M.-E. Halatsch
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Mol. Cancer Res.,
July 1, 2009;
7(7):
1000 - 1012.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-S. Guillamo, S. de Bouard, S. Valable, L. Marteau, P. Leuraud, Y. Marie, M.-F. Poupon, J.-J. Parienti, E. Raymond, and M. Peschanski
Molecular Mechanisms Underlying Effects of Epidermal Growth Factor Receptor Inhibition on Invasion, Proliferation, and Angiogenesis in Experimental Glioma
Clin. Cancer Res.,
June 1, 2009;
15(11):
3697 - 3704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. van den Bent, A. A. Brandes, R. Rampling, M. C.M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J.-F. Baurain, et al.
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
J. Clin. Oncol.,
March 10, 2009;
27(8):
1268 - 1274.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al.
Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma
Clin. Cancer Res.,
January 15, 2009;
15(2):
701 - 707.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res.,
February 15, 2008;
14(4):
957 - 960.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Wang, P. Guo, X. Wang, Q. Zhou, and J. M. Gallo
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models
Mol. Cancer Ther.,
February 1, 2008;
7(2):
407 - 417.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther.,
July 1, 2007;
6(7):
1909 - 1919.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Failly, S. Korur, V. Egler, J.-L. Boulay, M. M. Lino, R. Imber, and A. Merlo
Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells
Mol. Cancer Ther.,
February 1, 2007;
6(2):
773 - 781.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Clin. Cancer Res.,
January 15, 2007;
13(2):
378 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner
Recent Advances in the Treatment of Malignant Astrocytoma
J. Clin. Oncol.,
March 10, 2006;
24(8):
1253 - 1265.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Reardon and P. Y. Wen
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Oncologist,
February 1, 2006;
11(2):
152 - 164.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H.Y. Huang, D. J. Chute, et al.
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors.
N. Engl. J. Med.,
November 10, 2005;
353(19):
2012 - 2024.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
